Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Discovery
Sponsor : Sherpa Healthcare
Deal Size : $30.0 million
Deal Type : Series A Financing
Details : PAQ's novel autophagosome-tethering compounds (ATTECs) are small molecules with the potential to selectively catalyze autophagy-dependent degradation of a wide range of disease-causing substrates.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 15, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery
Sponsor : Sherpa Healthcare
Deal Size : $30.0 million
Deal Type : Series A Financing